Vistagen Therapeutics, Inc. Cash Flow Statement
VTGN|8 years of annual SEC 10-K data (FY2011-FY2023)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Vistagen Therapeutics, Inc. used $45M in operating cash flow and negative free cash flow of $45M in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$47.8M | -$17.9M | -$20.8M | -$10.3M | -$47.2M | -$42.7M | -$230.9K | -$230.9K |
| Depreciation & Amortization | $153.5K | $117.6K | $103.1K | $54.9K | $53.5K | $33.8K | $45.6K | $45.3K |
| Operating Cash Flow | -$45.3M | -$12.1M | -$15.8M | -$7.3M | -$4.8M | -$3.5M | -$3.6M | -$841.3K |
| Capital Expenditures | $0 | $275.4K | $0 | $239.1K | $26.3K | - | - | - |
| Free Cash Flow | -$45.3M | -$12.3M | -$15.8M | -$7.5M | -$4.8M | - | - | - |
| FCF Margin | -4080.8% | -3488.4% | - | -600.1% | - | - | - | - |